Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Резолюция совета экспертов по теме: «Новое в аллергологии» (13 июня 2017 г.)
Резолюция совета экспертов по теме: «Новое в аллергологии» (13 июня 2017 г.)
Ильина Н.И., Емельянов А.В., Княжеская Н.П. и др. Резолюция совета экспертов по теме: «Новое в аллергологии» (13 июня 2017 г.). Consilium Medicum. 2017; 19 (11.1. Болезни органов дыхания): 25–27. DOI: 10.26442/2075-1753_19.11.1.25-27
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Козулина И.Е., Курбачева О.М., Ильина Н.И. Аллергия сегодня. Анализ новых эпидемиологических данных. Рос. аллергол. журн. 2014; 3: 3–10. / Kozulina I.E., Kurbacheva O.M., Il'ina N.I. Allergiia segodnia. Analiz novykh epidemiologicheskikh dannykh. Ros. allergol. zhurn. 2014; 3: 3–10. [in Russian]
2. Аллергология. Федеральные клинические рекомендации. Под ред. акад. РАН Р.М.Хаитова, проф. Н.И.Ильиной. М.: Фармарус Принт Медиа, 2014. / Allergologiia. Federal'nye klinicheskie rekomendatsii. Pod red. akad. RAN R.M.Khaitova, prof. N.I.Il'inoi. M.: Farmarus Print Media, 2014. [in Russian]
3. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс, 2016. / Federal'nye klinicheskie rekomendatsii. Dermatovenerologiia 2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress, 2016. [in Russian]
4. Арефьева Н.А. и др. Аллергический риноконъюнктивит: клинические рекомендации. Под ред. А.С.Лопатина; Российское общество ринологов. М: Практическая медицина, 2015. / Arefeva N.A. i dr. Allergicheskii rinokon"iunktivit: klinicheskie rekomendatsii. Pod red. A.S.Lopatina; Rossiiskoe obshchestvo rinologov. M: Prakticheskaia meditsina, 2015. [in Russian]
5. Brozek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017. DOI: 10.1016/j.jaci.2017.03.050.
6. Zuberbier T, Aberer W, Asero R et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69: 868–87.
7. Инструкция по применению лекарственного препарата для медицинского применения Никсар® (рег. номер ЛП-003735-140716; утв. Минздравом РФ 14.07.2016). / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Niksar® (reg. nomer LP-003735-140716; utv. Minzdravom RF 14.07.2016). [in Russian]
8. Corcostegui, R et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6 (6): 371–384
9. Alvarez-Mon M et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 2009; 64 (Suppl. 90): 555.
10. Horak F et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010, 59, 391–8.
11. Kuna P et al. Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338–47.
12. Bachert C et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64 (1): 158–65.
13. Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010, 65 (4): 516–28.
14. Krause K et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–8.
15. Bousquet J et al. World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62.
16. Conen S et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517–23.
17. Farre M et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2014; 78: 970–80.
18. Garcia-Gea C et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol 2014; 29: 120–32.
19. Bousquet J et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131–9.
20. Tyl B et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52, 893–903.
21. Sastre J et al. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
2. Allergologiia. Federal'nye klinicheskie rekomendatsii. Pod red. akad. RAN R.M.Khaitova, prof. N.I.Il'inoi. M.: Farmarus Print Media, 2014. [in Russian]
3. Federal'nye klinicheskie rekomendatsii. Dermatovenerologiia 2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress, 2016. [in Russian]
4. Arefeva N.A. i dr. Allergicheskii rinokon"iunktivit: klinicheskie rekomendatsii. Pod red. A.S.Lopatina; Rossiiskoe obshchestvo rinologov. M: Prakticheskaia meditsina, 2015. [in Russian]
5. Brozek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017. DOI: 10.1016/j.jaci.2017.03.050.
6. Zuberbier T, Aberer W, Asero R et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69: 868–87.
7. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Niksar® (reg. nomer LP-003735-140716; utv. Minzdravom RF 14.07.2016). [in Russian]
8. Corcostegui, R et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6 (6): 371–384
9. Alvarez-Mon M et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 2009; 64 (Suppl. 90): 555.
10. Horak F et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010, 59, 391–8.
11. Kuna P et al. Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338–47.
12. Bachert C et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64 (1): 158–65.
13. Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010, 65 (4): 516–28.
14. Krause K et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–8.
15. Bousquet J et al. World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62.
16. Conen S et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517–23.
17. Farre M et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2014; 78: 970–80.
18. Garcia-Gea C et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol 2014; 29: 120–32.
19. Bousquet J et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131–9.
20. Tyl B et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52, 893–903.
21. Sastre J et al. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
2. Аллергология. Федеральные клинические рекомендации. Под ред. акад. РАН Р.М.Хаитова, проф. Н.И.Ильиной. М.: Фармарус Принт Медиа, 2014. / Allergologiia. Federal'nye klinicheskie rekomendatsii. Pod red. akad. RAN R.M.Khaitova, prof. N.I.Il'inoi. M.: Farmarus Print Media, 2014. [in Russian]
3. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс, 2016. / Federal'nye klinicheskie rekomendatsii. Dermatovenerologiia 2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress, 2016. [in Russian]
4. Арефьева Н.А. и др. Аллергический риноконъюнктивит: клинические рекомендации. Под ред. А.С.Лопатина; Российское общество ринологов. М: Практическая медицина, 2015. / Arefeva N.A. i dr. Allergicheskii rinokon"iunktivit: klinicheskie rekomendatsii. Pod red. A.S.Lopatina; Rossiiskoe obshchestvo rinologov. M: Prakticheskaia meditsina, 2015. [in Russian]
5. Brozek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017. DOI: 10.1016/j.jaci.2017.03.050.
6. Zuberbier T, Aberer W, Asero R et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69: 868–87.
7. Инструкция по применению лекарственного препарата для медицинского применения Никсар® (рег. номер ЛП-003735-140716; утв. Минздравом РФ 14.07.2016). / Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Niksar® (reg. nomer LP-003735-140716; utv. Minzdravom RF 14.07.2016). [in Russian]
8. Corcostegui, R et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6 (6): 371–384
9. Alvarez-Mon M et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 2009; 64 (Suppl. 90): 555.
10. Horak F et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010, 59, 391–8.
11. Kuna P et al. Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338–47.
12. Bachert C et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64 (1): 158–65.
13. Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010, 65 (4): 516–28.
14. Krause K et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–8.
15. Bousquet J et al. World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62.
16. Conen S et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517–23.
17. Farre M et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2014; 78: 970–80.
18. Garcia-Gea C et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol 2014; 29: 120–32.
19. Bousquet J et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131–9.
20. Tyl B et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52, 893–903.
21. Sastre J et al. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
________________________________________________
2. Allergologiia. Federal'nye klinicheskie rekomendatsii. Pod red. akad. RAN R.M.Khaitova, prof. N.I.Il'inoi. M.: Farmarus Print Media, 2014. [in Russian]
3. Federal'nye klinicheskie rekomendatsii. Dermatovenerologiia 2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem. 5-e izd., pererab. i dop. M.: Delovoi ekspress, 2016. [in Russian]
4. Arefeva N.A. i dr. Allergicheskii rinokon"iunktivit: klinicheskie rekomendatsii. Pod red. A.S.Lopatina; Rossiiskoe obshchestvo rinologov. M: Prakticheskaia meditsina, 2015. [in Russian]
5. Brozek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017. DOI: 10.1016/j.jaci.2017.03.050.
6. Zuberbier T, Aberer W, Asero R et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014, 69: 868–87.
7. Instruktsiia po primeneniiu lekarstvennogo preparata dlia meditsinskogo primeneniia Niksar® (reg. nomer LP-003735-140716; utv. Minzdravom RF 14.07.2016). [in Russian]
8. Corcostegui, R et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist. Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005; 6 (6): 371–384
9. Alvarez-Mon M et al. Bilastine a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes. Allergy 2009; 64 (Suppl. 90): 555.
10. Horak F et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010, 59, 391–8.
11. Kuna P et al. Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009; 39: 1338–47.
12. Bachert C et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64 (1): 158–65.
13. Zuberbier T et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010, 65 (4): 516–28.
14. Krause K et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013; 68: 921–8.
15. Bousquet J et al. World Health Organization Collaborating Center for Asthma and Rhinitis. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049–62.
16. Conen S et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011; 25: 1517–23.
17. Farre M et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol 2014; 78: 970–80.
18. Garcia-Gea C et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol 2014; 29: 120–32.
19. Bousquet J et al. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Curr Med Res Opin 2012; 28: 131–9.
20. Tyl B et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol 2012; 52, 893–903.
21. Sastre J et al. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
Авторы
Н.И.Ильина1, А.В.Емельянов2, Н.П.Княжеская3, А.С.Лопатин4, Н.М.Ненашева5, Ю.Н.Перламутров6, В.М.Свистушкин*7
1 ФГБУ «ГНЦ Институт иммунологии» ФМБА России. 115478, Россия, Москва, Каширское ш., д. 24, корп. 2;
2 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
4 ФГБУ «Поликлиника №1 Управления делами Президента РФ». 119002, Россия, Москва, пер. Сивцев Вражек, д. 26/28;
5 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
6 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России; 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
7 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*svvm3@yandex.ru
1 Institute of Immunology of FMBA of Russia. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 24, korp. 2;
2 I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
3 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
4 Out-Patient Сlinic №1 of Administration of the President of Russian Federation. 119002, Russian Federation, Moscow, per. Sivcev Vrazhek, d. 26/28;
5 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
6 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
7 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*svvm3@yandex.ru
1 ФГБУ «ГНЦ Институт иммунологии» ФМБА России. 115478, Россия, Москва, Каширское ш., д. 24, корп. 2;
2 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1;
4 ФГБУ «Поликлиника №1 Управления делами Президента РФ». 119002, Россия, Москва, пер. Сивцев Вражек, д. 26/28;
5 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1;
6 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» Минздрава России; 127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1;
7 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*svvm3@yandex.ru
________________________________________________
1 Institute of Immunology of FMBA of Russia. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 24, korp. 2;
2 I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
3 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1;
4 Out-Patient Сlinic №1 of Administration of the President of Russian Federation. 119002, Russian Federation, Moscow, per. Sivcev Vrazhek, d. 26/28;
5 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1;
6 A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation. 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1;
7 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*svvm3@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.